LENZ Therapeutics, Inc. (LENZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 8M 16M 24M Q4 '25: 19.1M Q1 '26: 21M Q2 '26: 21.5M Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -49.8M Q4 '21: -60.4M Q1 '22: -77M Q2 '22: -86.3M Q3 '22: -97.8M Q4 '22: -105.6M Q1 '23: -92.3M Q2 '23: -80.5M Q3 '23: -74.2M Q4 '23: -72.4M Q1 '24: -75.9M Q2 '24: -75.3M Q3 '24: -68.4M Q4 '24: -58.6M Q1 '25: -59.5M Q2 '25: -62M Q3 '25: -67.9M Q4 '25: -91.1M Q1 '26: -118.3M Q2 '26: -135.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -115.4M Q4 '21: -70.8M Q1 '22: -76.9M Q2 '22: -85.3M Q3 '22: -95.4M Q4 '22: -101.1M Q1 '23: -87.9M Q2 '23: -76.7M Q3 '23: -70.9M Q4 '23: -70M Q1 '24: -73.9M Q2 '24: -69.5M Q3 '24: -60.8M Q4 '24: -49.8M Q1 '25: -47.7M Q2 '25: -52.4M Q3 '25: -58.9M Q4 '25: -82.1M Q1 '26: -109M Q2 '26: -126M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -42.5M Q4 '21: -52.9M Q1 '22: -66M Q2 '22: -74.3M Q3 '22: -81.1M Q4 '22: -88M Q1 '23: -79.5M Q2 '23: -71M Q3 '23: -61.8M Q4 '23: -60.4M Q1 '24: -71.5M Q2 '24: -73.8M Q3 '24: -71.3M Q4 '24: -59.4M Q1 '25: -51.5M Q2 '25: -47.2M Q3 '25: -45.2M Q4 '25: -69.2M Q1 '26: -86.7M Q2 '26: -113.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -47.9M Q4 '21: -58.6M Q1 '22: -74.7M Q2 '22: -83.6M Q3 '22: -87.7M Q4 '22: -94.6M Q1 '23: -82.9M Q2 '23: -72.9M Q3 '23: -62.9M Q4 '23: -60.4M Q1 '24: -71.5M Q2 '24: -73.9M Q3 '24: -71.6M Q4 '24: -59.9M Q1 '25: -52.1M Q2 '25: -47.9M Q3 '25: -46.2M Q4 '25: -70M Q1 '26: -87.4M Q2 '26: -114.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 5.1M Q3 '21: 52.8M Q1 '22: 54M Q2 '22: 54.6M Q3 '22: 55.2M Q1 '23: 2M Q2 '23: 2M Q3 '23: 2M Q1 '24: 4.7M Q2 '24: 25.6M Q3 '24: 27.2M Q1 '25: 27.5M Q2 '25: 28.1M Q3 '25: 28.5M Q1 '26: 31.4M Q2 '26: 31.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '20: -29.93 Q1 '21: -34.71 Q2 '21: -37.60 Q3 '21: -36.88 Q4 '21: -2.45 Q1 '22: 2.82 Q2 '22: 5.79 Q3 '22: 5.62 Q4 '22: -1.85 Q1 '23: -7.87 Q2 '23: -14.92 Q3 '23: -24.09 Q4 '23: -35.70 Q1 '24: -32.73 Q2 '24: -25.60 Q3 '24: -16.36 Q4 '25: -2.85 Q1 '26: -3.64 Q2 '26: -4.13 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.